Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

SVR12 is higher than SVR24 in treatment-naïve hepatitis C genotype 1 patients treated with peginterferon plus ribavirin.

Thorlund K, Druyts E, Mills EJ.

Clin Epidemiol. 2014 Jan 15;6:49-58. doi: 10.2147/CLEP.S53302. eCollection 2014.

2.

Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis.

Suwanthawornkul T, Anothaisintawee T, Sobhonslidsuk A, Thakkinstian A, Teerawattananon Y.

PLoS One. 2015 Dec 31;10(12):e0145953. doi: 10.1371/journal.pone.0145953. eCollection 2015. Review.

3.

Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis.

Druyts E, Mills EJ, Nachega J, O'Regan C, Cooper CL.

Clin Exp Gastroenterol. 2012;5:11-21. doi: 10.2147/CEG.S28253. Epub 2012 Feb 14.

4.

Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.

Hauser G, Awad T, Brok J, Thorlund K, Štimac D, Mabrouk M, Gluud C, Gluud LL.

Cochrane Database Syst Rev. 2014 Feb 28;(2):CD005441. Review.

PMID:
24585509
5.

A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.

Zhao S, Liu E, Chen P, Cheng D, Lu S, Yu Q, Wang Y, Wei K, Yang P.

Clin Ther. 2010 Aug;32(9):1565-77. doi: 10.1016/j.clinthera.2010.08.009. Review.

PMID:
20974315
6.

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.

Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, Janczewska E, Villamil F, Scott J, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M.

Lancet. 2014 Aug 2;384(9941):414-26. doi: 10.1016/S0140-6736(14)60538-9. Epub 2014 Jun 4. Erratum in: Lancet. 2016 Apr 30;387(10030):1816.

PMID:
24907224
7.

Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin.

Kanda T, Nakamoto S, Sasaki R, Nakamura M, Yasui S, Haga Y, Ogasawara S, Tawada A, Arai M, Mikami S, Imazeki F, Yokosuka O.

Int J Med Sci. 2016 Apr 10;13(4):310-5. doi: 10.7150/ijms.14953. eCollection 2016.

8.

Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C.

Hauser G, Awad T, Thorlund K, Štimac D, Mabrouk M, Gluud C.

Cochrane Database Syst Rev. 2014 Feb 28;(2):CD005642. doi: 10.1002/14651858.CD005642.pub3. Review.

PMID:
24585451
9.
10.

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.

Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, Moroz L, Craxi A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Scott J, Sinha R, Beumont-Mauviel M.

Lancet. 2014 Aug 2;384(9941):403-13. doi: 10.1016/S0140-6736(14)60494-3. Epub 2014 Jun 4. Erratum in: Lancet. 2016 Apr 30;387(10030):1816.

PMID:
24907225
11.

The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluation.

Hartwell D, Cooper K, Frampton GK, Baxter L, Loveman E.

Health Technol Assess. 2014 Oct;18(65):i-xxii, 1-202. doi: 10.3310/hta18650. Review.

12.

Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.

Katz LH, Goldvaser H, Gafter-Gvili A, Tur-Kaspa R.

Cochrane Database Syst Rev. 2012 Sep 12;(9):CD008516. doi: 10.1002/14651858.CD008516.pub2. Review.

PMID:
22972122
13.

Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.

Sullivan SD, Jensen DM, Bernstein DE, Hassanein TI, Foster GR, Lee SS, Cheinquer H, Craxi A, Cooksley G, Klaskala W, Pettit K, Patel KK, Green J.

Am J Gastroenterol. 2004 Aug;99(8):1490-6.

PMID:
15307866
14.

Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort.

Foster GR, Coppola C, Derbala M, Ferenci P, Orlandini A, Reddy KR, Tallarico L, Shiffman ML, Ahlers S, Bakalos G, Hassanein T; GUARD-C Study Group.

PLoS One. 2016 Mar 28;11(3):e0151703. doi: 10.1371/journal.pone.0151703. eCollection 2016.

15.

Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.

Dore GJ, Lawitz E, Hézode C, Shafran SD, Ramji A, Tatum HA, Taliani G, Tran A, Brunetto MR, Zaltron S, Strasser SI, Weis N, Ghesquiere W, Lee SS, Larrey D, Pol S, Harley H, George J, Fung SK, de Lédinghen V, Hagens P, McPhee F, Hernandez D, Cohen D, Cooney E, Noviello S, Hughes EA.

Gastroenterology. 2015 Feb;148(2):355-366.e1. doi: 10.1053/j.gastro.2014.10.007. Epub 2014 Oct 13.

PMID:
25311593
16.

Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.

Jensen D, Sherman KE, Hézode C, Pol S, Zeuzem S, de Ledinghen V, Tran A, Elkhashab M, Younes ZH, Kugelmas M, Mauss S, Everson G, Luketic V, Vierling J, Serfaty L, Brunetto M, Heo J, Bernstein D, McPhee F, Hennicken D, Mendez P, Hughes E, Noviello S; HALLMARK-QUAD Study Team.

J Hepatol. 2015 Jul;63(1):30-7. doi: 10.1016/j.jhep.2015.02.018. Epub 2015 Feb 19.

PMID:
25703086
17.

Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.

Jacobson I, Zeuzem S, Flisiak R, Knysz B, Lueth S, Zarebska-Michaluk D, Janczewska E, Ferenci P, Diago M, Zignego AL, Safadi R, Baruch Y, Abdurakhmanov D, Shafran S, Thabut D, Bruck R, Gadano A, Thompson AJ, Kopit J, McPhee F, Michener T, Hughes EA, Yin PD, Noviello S.

World J Gastroenterol. 2016 Mar 28;22(12):3418-31. doi: 10.3748/wjg.v22.i12.3418.

18.

Efficacy and Tolerability of Peginterferon α -2a and Peginterferon α -2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled Trials.

Yang Z, Zhuang L, Yang L, Chen X.

Gastroenterol Res Pract. 2013;2013:739029. doi: 10.1155/2013/739029. Epub 2013 Apr 11.

19.

Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial.

Liu CH, Huang CF, Liu CJ, Dai CY, Huang JF, Lin JW, Liang CC, Yang SS, Lin CL, Su TH, Yang HC, Chen PJ, Chen DS, Chuang WL, Kao JH, Yu ML.

Sci Rep. 2015 Oct 15;5:15255. doi: 10.1038/srep15255.

20.

Nitazoxanide for chronic hepatitis C.

Nikolova K, Gluud C, Grevstad B, Jakobsen JC.

Cochrane Database Syst Rev. 2014 Apr 6;(4):CD009182. doi: 10.1002/14651858.CD009182.pub2. Review.

PMID:
24706397

Supplemental Content

Support Center